WO2009100430A3 - miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS - Google Patents

miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS Download PDF

Info

Publication number
WO2009100430A3
WO2009100430A3 PCT/US2009/033556 US2009033556W WO2009100430A3 WO 2009100430 A3 WO2009100430 A3 WO 2009100430A3 US 2009033556 W US2009033556 W US 2009033556W WO 2009100430 A3 WO2009100430 A3 WO 2009100430A3
Authority
WO
WIPO (PCT)
Prior art keywords
lnneg
lnpos
differentially expressed
lymph nodes
cancer
Prior art date
Application number
PCT/US2009/033556
Other languages
French (fr)
Other versions
WO2009100430A2 (en
Inventor
Sylvie Beaudenon
Laura Elizondo
Martina Doleshal
David Brown
Emmanuel Labourier
Original Assignee
Asuragen, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asuragen, Inc filed Critical Asuragen, Inc
Priority to EP09709348.8A priority Critical patent/EP2260110B1/en
Publication of WO2009100430A2 publication Critical patent/WO2009100430A2/en
Publication of WO2009100430A3 publication Critical patent/WO2009100430A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/10—Production naturally occurring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention provides diagnostics and/or prognostic methods by identifying miRNAs that are differentially expressed or mis-regulated in various states of diseased, normal, cancerous, and/or abnormal tissues, including but not limited to cervix, skin, colon, breast, bladder, esophagus, liver, ovary, prostate, lung, pancreas, thyroid, kidney, stomach, testicle, uterus, spleen, tongue, brain, thymus, trachea and/or small intestine. In certain apsects, differential miRNA expression is initially determined by comparing miRNA expression between a normal tissue and cancer negative lymph node (LNneg), a normal tissue and a cancer positive lymph node (LNpos), a cancerous tissue and LNneg and/or LNpos, LNneg and LNpos. The methods of the invention are used to identify the presence or absence of non-lymphoid cells from other organs or tissues, and/or metastatic cancer cells present in lymph nodes.
PCT/US2009/033556 2008-02-08 2009-02-09 miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS WO2009100430A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP09709348.8A EP2260110B1 (en) 2008-02-08 2009-02-09 miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2719808P 2008-02-08 2008-02-08
US61/027,198 2008-02-08

Publications (2)

Publication Number Publication Date
WO2009100430A2 WO2009100430A2 (en) 2009-08-13
WO2009100430A3 true WO2009100430A3 (en) 2009-10-01

Family

ID=40632164

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/033556 WO2009100430A2 (en) 2008-02-08 2009-02-09 miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS

Country Status (3)

Country Link
US (2) US20090263803A1 (en)
EP (1) EP2260110B1 (en)
WO (1) WO2009100430A2 (en)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2290067B1 (en) 2004-05-28 2014-12-10 Asuragen, Inc. Methods and compositions involving microRNA
ES2534304T3 (en) 2004-11-12 2015-04-21 Asuragen, Inc. Procedures and compositions involving miRNA and miRNA inhibitor molecules
JP5489459B2 (en) 2005-08-01 2014-05-14 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション MicroRNA-based methods and compositions for diagnosis, prognosis and treatment of breast cancer
EP2796554A3 (en) 2005-09-12 2014-12-10 The Ohio State University Research Foundation Compositions for use in treating BCL2-associated cancers
EP2487263B1 (en) 2006-01-05 2014-03-19 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers of the pancreas
CN101384273B (en) 2006-01-05 2013-07-10 俄亥俄州立大学研究基金会 Microrna expression abnormalities in pancreatic endocrine and acinar tumors
WO2007081720A2 (en) 2006-01-05 2007-07-19 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
ES2446362T3 (en) 2006-03-20 2014-03-07 The Ohio State University Research Foundation Traces of microRNA during human megakaryocytogenesis
EP2455493B1 (en) 2006-07-13 2014-01-08 The Ohio State University Research Foundation Micro-RNA-based methods and compositions for the diagnosis and treatment of colon related diseases
US8071292B2 (en) 2006-09-19 2011-12-06 The Ohio State University Research Foundation Leukemia diagnostic methods
ES2425416T3 (en) 2006-11-01 2013-10-15 The Ohio State University Research Foundation Signature of microRNA expression to predict survival and metastasis in hepatocellular carcinoma
CN105256004A (en) 2007-01-31 2016-01-20 俄亥俄州立大学研究基金会 Microrna-based methods and compositions for the diagnosis, prognosis and treatment of acute myeloid leukemia
JP5690588B2 (en) 2007-06-08 2015-03-25 アメリカ合衆国 Method for determining hepatocellular carcinoma subtype and detecting hepatoma stem cells
CA2690749A1 (en) 2007-06-15 2008-12-24 The Ohio State University Research Foundation Oncogenic all-1 fusion proteins for targeting drosha-mediated microrna processing
US8367632B2 (en) 2007-07-31 2013-02-05 Ohio State University Research Foundation Methods for reverting methylation by targeting methyltransferases
CN101835902B (en) 2007-08-03 2014-03-26 俄亥俄州立大学研究基金会 Ultraconserved regions encoding NCRNAS
EP2183593B1 (en) 2007-08-22 2016-01-13 The Ohio State University Research Foundation Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias
AU2008316577B2 (en) 2007-10-26 2014-04-10 The Ohio State University Research Foundation Methods for identifying fragile histidine triad (FHIT) interaction and uses thereof
WO2009119809A1 (en) * 2008-03-27 2009-10-01 株式会社ミラキュア Marker for determination of breast cancer, test method, and test kit
JP5745401B2 (en) 2008-06-11 2015-07-08 アメリカ合衆国 Use of the MiR-26 family as a predictive marker for hepatocellular carcinoma and responsiveness to therapy
CA2749841A1 (en) * 2009-01-16 2010-07-22 Cepheid Methods of detecting cervical cancer
US20100240049A1 (en) 2009-01-16 2010-09-23 Cepheid Methods of Detecting Cervical Cancer
WO2011063382A1 (en) 2009-11-23 2011-05-26 The Ohio State University Materials and methods useful for affecting tumor cell growth, migration and invasion
US8841269B2 (en) * 2010-02-23 2014-09-23 Creighton University Polynucleotides for use in treating and diagnosing cancers
WO2011130426A2 (en) * 2010-04-13 2011-10-20 New York University Compositions and methods for treatment of melanoma
WO2011128900A2 (en) * 2010-04-15 2011-10-20 Hadasit Medical Research Services And Development Ltd. Early detection and staging of colorectal cancer using a panel of micro rnas
JP5755849B2 (en) * 2010-07-06 2015-07-29 東レ株式会社 Composition or kit for determining sensitivity to adjuvant chemotherapy for gastric cancer
NZ704322A (en) * 2010-07-06 2016-07-29 Interna Technologies Bv Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
WO2012010584A1 (en) * 2010-07-20 2012-01-26 Febit Holding Gmbh Complex mirna sets as novel biomarkers for gastric cancer
WO2012017430A2 (en) 2010-08-01 2012-02-09 Tel Hashomer Medical Research Infrastructure And Services Ltd. Microrna patterns for the diagnosis, prognosis and treatment of melanoma
WO2012065049A1 (en) 2010-11-12 2012-05-18 The Ohio State University Research Foundation Materials and methods related to microrna-21, mismatch repair, and colorectal cancer
BR112013011942A2 (en) 2010-11-15 2016-11-01 Univ Michigan formulation, drug dosage form for oral transmucosal administration, transmucosal drug delivery system, method of treatment and prophylaxis of a disease or disorder, method of treatment, formulation, method for treatment or prevention of head and neck squamous cell carcinoma (hnscc), method for chemoprevention of an oral cancer or precancerous condition, method for increasing the concentration of a retinide composition, method of treatment and prophylaxis of a disease or condition, ratification method of a subject presenting a symptomatic medical condition , method of treating an oral cancer or precancerous condition in a patient, method for making an oral drug delivery system, method for increasing the release and permeation of a retinide composition.
WO2012071492A1 (en) 2010-11-23 2012-05-31 Georgia Tech Research Corporation Mir-200 family induces mesenchymal-to-epithelial transition (met) in ovarian cancer cells
US8664192B2 (en) 2011-03-07 2014-03-04 The Ohio State University Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer
WO2012128902A1 (en) * 2011-03-18 2012-09-27 Baylor Research Institute Changes in the expression of mir-200c/141 cluster of micrornas as biomarkers for epithelial-to-mesenchymal transition in human colorectal cancer metastasis
WO2012161124A1 (en) * 2011-05-20 2012-11-29 国立大学法人愛媛大学 Composition containing micro rna or expression system thereof
CA2852066A1 (en) 2011-10-14 2013-04-18 The Ohio State University Methods and materials related to ovarian cancer
CA2859430A1 (en) 2011-12-13 2013-06-20 Ohio State Innovation Foundation Methods and compositions related to mir-21 and mir-29a, exosome inhibition, and cancer metastasis
CN104685065B (en) 2012-01-20 2017-02-22 俄亥俄州立大学 Breast cancer biomarker signatures for invasiveness and prognosis
EP2872634B1 (en) * 2012-07-12 2018-08-22 Baylor College Of Medicine Micrornas sensitize cancers to therapy
WO2014030602A1 (en) 2012-08-20 2014-02-27 独立行政法人国立がん研究センター Agent for treating cancer
WO2014093924A1 (en) 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
HRP20220607T1 (en) 2012-11-26 2022-06-24 Modernatx, Inc. Terminally modified rna
EP2946014A2 (en) 2013-01-17 2015-11-25 Moderna Therapeutics, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
ES2877689T3 (en) * 2014-05-02 2021-11-17 Univ Heidelberg Ruprecht Karls Circulating miRNAs as an early detection marker and prognostic marker
CN104073432B (en) * 2014-05-07 2017-01-18 上海缔达生物科技有限公司 Kit for detecting liver cancer marker nucleic acid molecules and detection method of kit
EP3041948B1 (en) 2014-11-10 2019-01-09 Modernatx, Inc. Alternative nucleic acid molecules containing reduced uracil content and uses thereof
BR102015003310A2 (en) * 2015-02-13 2016-08-16 Hospital De Câncer De Barretos Fundação Pio Xii method of lymph node metastatic cell detection in patients with head and neck squamous cell carcinoma and use of micrornas as markers
EP3405579A1 (en) 2016-01-22 2018-11-28 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
EP3443001A4 (en) 2016-04-11 2020-04-29 Obsidian Therapeutics, Inc. Regulated biocircuit systems
DK3458083T3 (en) 2016-05-18 2023-01-30 Modernatx Inc POLYNUCLEOTIDES ENCODING INTERLEUKIN-12 (IL12) AND USES THEREOF
EP3468537A1 (en) 2016-06-14 2019-04-17 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
US11174469B2 (en) 2016-06-29 2021-11-16 Crispr Therapeutics Ag Materials and methods for treatment of Amyotrophic Lateral Sclerosis (ALS) and other related disorders
WO2018002783A1 (en) 2016-06-29 2018-01-04 Crispr Therapeutics Ag Materials and methods for treatment of friedreich ataxia and other related disorders
EP3478829A1 (en) 2016-06-29 2019-05-08 Crispr Therapeutics AG Materials and methods for treatment of myotonic dystrophy type 1 (dm1) and other related disorders
JP2019520079A (en) 2016-07-06 2019-07-18 クリスパー セラピューティクス アクチェンゲゼルシャフト Substances and methods for treating pain related disorders
AU2017292169B2 (en) 2016-07-06 2021-12-23 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of pain related disorders
CN106086226B (en) * 2016-08-25 2020-02-14 朱伟 Plasma miRNA marker related to IgA nephropathy auxiliary diagnosis and application thereof
KR20190086681A (en) 2016-10-26 2019-07-23 모더나티엑스, 인크. Messenger ribonucleic acid and method of use thereof for improving immune response
WO2018089540A1 (en) 2016-11-08 2018-05-17 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
US20190351039A1 (en) 2017-02-01 2019-11-21 Modernatx, Inc. Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
EP3585900B1 (en) 2017-02-22 2022-12-21 CRISPR Therapeutics AG Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
EP3585898A1 (en) 2017-02-22 2020-01-01 CRISPR Therapeutics AG Materials and methods for treatment of spinocerebellar ataxia type 1 (sca1) and other spinocerebellar ataxia type 1 protein (atxn1) gene related conditions or disorders
WO2018154459A1 (en) 2017-02-22 2018-08-30 Crispr Therapeutics Ag Materials and methods for treatment of primary hyperoxaluria type 1 (ph1) and other alanine-glyoxylate aminotransferase (agxt) gene related conditions or disorders
AU2018224387A1 (en) 2017-02-22 2019-09-05 Crispr Therapeutics Ag Compositions and methods for gene editing
WO2018154418A1 (en) 2017-02-22 2018-08-30 Crispr Therapeutics Ag Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders
US20200131498A1 (en) 2017-06-14 2020-04-30 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase
MX2020002348A (en) 2017-08-31 2020-10-08 Modernatx Inc Methods of making lipid nanoparticles.
JP2021503945A (en) 2017-11-21 2021-02-15 クリスパー セラピューティクス アーゲー Materials and Methods for the Treatment of Autosomal Dominant Retinitis Pigmentosa
WO2019123429A1 (en) 2017-12-21 2019-06-27 Casebia Therapeutics Llp Materials and methods for treatment of usher syndrome type 2a
WO2019123430A1 (en) 2017-12-21 2019-06-27 Casebia Therapeutics Llp Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp)
CA3089117A1 (en) 2018-01-30 2019-08-08 Modernatx, Inc. Compositions and methods for delivery of agents to immune cells
WO2019200171A1 (en) 2018-04-11 2019-10-17 Modernatx, Inc. Messenger rna comprising functional rna elements
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
WO2020061457A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
US20210386788A1 (en) 2018-10-24 2021-12-16 Obsidian Therapeutics, Inc. Er tunable protein regulation
EP3917503B1 (en) 2019-01-31 2024-05-08 ModernaTX, Inc. Methods of preparing lipid nanoparticles
CA3132840A1 (en) 2019-03-08 2020-09-17 Obsidian Therapeutics, Inc. Human carbonic anhydrase 2 compositions and methods for tunable regulation
WO2020263883A1 (en) 2019-06-24 2020-12-30 Modernatx, Inc. Endonuclease-resistant messenger rna and uses thereof
WO2020263985A1 (en) 2019-06-24 2020-12-30 Modernatx, Inc. Messenger rna comprising functional rna elements and uses thereof
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
KR20220133957A (en) 2020-01-31 2022-10-05 모더나티엑스, 인크. Method for preparing lipid nanoparticles
CN116710079A (en) 2020-07-24 2023-09-05 斯特兰德生物科技公司 Lipid nanoparticles comprising modified nucleotides
US20230277457A1 (en) 2020-08-06 2023-09-07 Modernatx, Inc. Methods of preparing lipid nanoparticles
CN112391470A (en) * 2020-11-11 2021-02-23 广东医科大学 Pancreatic cancer miRNA prognosis model establishment and targeted gene screening method
WO2022150712A1 (en) 2021-01-08 2022-07-14 Strand Therapeutics, Inc. Expression constructs and uses thereof
EP4334446A1 (en) 2021-05-03 2024-03-13 CureVac SE Improved nucleic acid sequence for cell type specific expression
WO2022246002A2 (en) * 2021-05-20 2022-11-24 City Of Hope Methods and compositions for determining cancer risk
WO2023212618A1 (en) 2022-04-26 2023-11-02 Strand Therapeutics Inc. Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof
WO2024026482A1 (en) 2022-07-29 2024-02-01 Modernatx, Inc. Lipid nanoparticle compositions comprising surface lipid derivatives and related uses
WO2024026487A1 (en) 2022-07-29 2024-02-01 Modernatx, Inc. Lipid nanoparticle compositions comprising phospholipid derivatives and related uses
WO2024026475A1 (en) 2022-07-29 2024-02-01 Modernatx, Inc. Compositions for delivery to hematopoietic stem and progenitor cells (hspcs) and related uses

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070054287A1 (en) * 2005-05-31 2007-03-08 Applera Corporation Method for identifying medically important cell populations using micro rna as tissue specific biomarkers
WO2007073737A1 (en) * 2005-12-29 2007-07-05 Exiqon A/S Detection of tissue origin of cancer
US20070161004A1 (en) * 2004-05-28 2007-07-12 David Brown Methods and compositions involving microRNA

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011769A (en) * 1985-12-05 1991-04-30 Meiogenics U.S. Limited Partnership Methods for detecting nucleic acid sequences
US4999290A (en) * 1988-03-31 1991-03-12 The Board Of Regents, The University Of Texas System Detection of genomic abnormalities with unique aberrant gene transcripts
US6040138A (en) * 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5188934A (en) * 1989-11-14 1993-02-23 Applied Biosystems, Inc. 4,7-dichlorofluorescein dyes as molecular probes
US5486603A (en) * 1990-01-08 1996-01-23 Gilead Sciences, Inc. Oligonucleotide having enhanced binding affinity
US5859221A (en) * 1990-01-11 1999-01-12 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
WO1992007095A1 (en) * 1990-10-15 1992-04-30 Stratagene Arbitrarily primed polymerase chain reaction method for fingerprinting genomes
US5538848A (en) * 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
DE69632870T2 (en) * 1995-03-17 2005-07-14 John Wayne Cancer Institute, Santa Monica DETECTION OF MELANOMA MEASURING TASTES USING MULTILARMARKER TEST
US6998268B2 (en) * 1995-07-03 2006-02-14 Dainippon Sumitomo Pharma Co. Ltd. Gene preparations
US5871697A (en) * 1995-10-24 1999-02-16 Curagen Corporation Method and apparatus for identifying, classifying, or quantifying DNA sequences in a sample without sequencing
EP0880598A4 (en) * 1996-01-23 2005-02-23 Affymetrix Inc Nucleic acid analysis techniques
US6020481A (en) * 1996-04-01 2000-02-01 The Perkin-Elmer Corporation Asymmetric benzoxanthene dyes
US5863727A (en) * 1996-05-03 1999-01-26 The Perkin-Elmer Corporation Energy transfer dyes with enhanced fluorescence
US6184037B1 (en) * 1996-05-17 2001-02-06 Genemedicine, Inc. Chitosan related compositions and methods for delivery of nucleic acids and oligonucleotides into a cell
US5739169A (en) * 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
DK1179600T3 (en) * 1996-06-04 2005-09-05 Univ Utah Res Found Hybridization monitoring during PCR
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
AU6545898A (en) * 1997-03-07 1998-09-22 Reprogen, Inc. Method for identifying hormonally modulated genes
NO972006D0 (en) * 1997-04-30 1997-04-30 Forskningsparken I Aas As New method for diagnosis of diseases
DE69841002D1 (en) * 1997-05-14 2009-09-03 Univ British Columbia Highly effective encapsulation of nucleic acids in lipid vesicles
WO1999022018A2 (en) * 1997-10-27 1999-05-06 Boston Probes, Inc. Methods, kits and compositions pertaining to pna molecular beacons
US5936087A (en) * 1997-11-25 1999-08-10 The Perkin-Elmer Corporation Dibenzorhodamine dyes
US6232066B1 (en) * 1997-12-19 2001-05-15 Neogen, Inc. High throughput assay system
US6238869B1 (en) * 1997-12-19 2001-05-29 High Throughput Genomics, Inc. High throughput assay system
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6037129A (en) * 1998-05-28 2000-03-14 Medical University Of South Carolina Multi-marker RT-PCR panel for detecting metastatic breast cancer
US6730477B1 (en) * 1998-08-04 2004-05-04 Diadexus, Inc. Method of diagnosing, monitoring and staging breast cancer
GB9904991D0 (en) * 1999-03-05 1999-04-28 Univ Nottingham Genetic screening
US6383752B1 (en) * 1999-03-31 2002-05-07 Hybridon, Inc. Pseudo-cyclic oligonucleobases
AU780454B2 (en) * 1999-06-03 2005-03-24 Jessie L.S. Au Methods and compositions for modulating cell proliferation and cell death
US6201112B1 (en) * 1999-07-22 2001-03-13 Agilent Technologies Inc. Method for 3′ end-labeling ribonucleic acids
US7005261B1 (en) * 1999-07-29 2006-02-28 British Biocell International Limited Method for detecting nucleic acid target sequences involving in vitro transcription from an RNA polymerase promoter
US6511832B1 (en) * 1999-10-06 2003-01-28 Texas A&M University System In vitro synthesis of capped and polyadenylated mRNAs using baculovirus RNA polymerase
US6528254B1 (en) * 1999-10-29 2003-03-04 Stratagene Methods for detection of a target nucleic acid sequence
US6191278B1 (en) * 1999-11-03 2001-02-20 Pe Corporation Water-soluble rhodamine dyes and conjugates thereof
GB9927444D0 (en) * 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
DE10100586C1 (en) * 2001-01-09 2002-04-11 Ribopharma Ag Inhibiting gene expression in cells, useful for e.g. treating tumors, by introducing double-stranded complementary oligoRNA having unpaired terminal bases
US7205105B2 (en) * 1999-12-08 2007-04-17 Epoch Biosciences, Inc. Real-time linear detection probes: sensitive 5′-minor groove binder-containing probes for PCR analysis
US20030084471A1 (en) * 2000-03-16 2003-05-01 David Beach Methods and compositions for RNA interference
WO2001070095A2 (en) * 2000-03-23 2001-09-27 Diadexus, Inc. Compositions and methods of diagnosing, monitoring, staging, imaging and treating prostate cancer
WO2001073060A2 (en) * 2000-03-24 2001-10-04 Millennium Pharmaceuticals, Inc. 18221, dual specificity phosphatase and uses thereof
AU2001251013A1 (en) * 2000-03-28 2001-10-08 Diadexus, Inc. Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer
DK2796553T3 (en) * 2000-03-30 2019-09-30 Whitehead Inst Biomedical Res RNA Sequence-Specific Mediators of RNA Interference
AU2001269690A1 (en) * 2000-05-10 2001-11-20 David A. Sirbasku Compositions and methods for demonstrating secretory immune system regulation of steroid hormone responsive cancer cell growth
US20030009295A1 (en) * 2001-03-14 2003-01-09 Victor Markowitz System and method for retrieving and using gene expression data from multiple sources
AU2001292842A1 (en) * 2000-09-19 2002-04-02 Diadexus, Inc. Compositions and methods relating to prostate specific genes and proteins
US7001724B1 (en) * 2000-11-28 2006-02-21 Applera Corporation Compositions, methods, and kits for isolating nucleic acids using surfactants and proteases
GB0029360D0 (en) * 2000-12-01 2001-01-17 Univ Nottingham Humanised antibodies and uses thereof
DK1407044T4 (en) * 2000-12-01 2017-12-04 Max-Planck-Gesellschaft Zur Förderung Der Wss E V RNA interference mediating small RNA molecules
US20030099976A1 (en) * 2001-01-17 2003-05-29 Tai-Jay Chang Androgen receptor complex-associated protein
US7015047B2 (en) * 2001-01-26 2006-03-21 Aviva Biosciences Corporation Microdevices having a preferential axis of magnetization and uses thereof
US20040058373A1 (en) * 2001-01-31 2004-03-25 Winkler Matthew M. Competitive amplification of fractionated targets from multiple nucleic acid samples
AU2002311869A1 (en) * 2001-04-27 2002-11-11 Sunnybrook And Women's College Health Sciences Centre Breast cancer-associated genes and uses thereof
US7171311B2 (en) * 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
US20040086504A1 (en) * 2001-06-21 2004-05-06 Deepak Sampath Cyr61 as a target for treatment and diagnosis of breast cancer
ATE448320T1 (en) * 2001-09-19 2009-11-15 Alexion Pharma Inc MANIPULATED MATRICES AND THEIR USE IN SINGLE-PRIMER AMPLIFICATION
CA2452288A1 (en) * 2001-09-20 2003-03-27 Cornell Research Foundation, Inc. Methods and compositions for treating and preventing skin disorders using binding agents specific for psma
US20040063654A1 (en) * 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
CA2469480A1 (en) * 2001-12-27 2003-07-17 Agy Therapeutics, Inc. Use of biomolecular targets in the treatment and visualization of tumors
US20040001841A1 (en) * 2002-04-03 2004-01-01 Usha Nagavarapu Use of biomolecular targets in the treatment and visualization of brain tumors
US20070025997A1 (en) * 2002-04-03 2007-02-01 Usha Nagavarapu Use of biomolecular targets in the treatment and visualization of brain tumors
AU2003265978A1 (en) * 2002-05-03 2003-11-17 Duke University A method of regulating gene expression
WO2004018704A2 (en) * 2002-05-20 2004-03-04 Northrop Grumman Corporation Point source biological agent detection system
US20040029128A1 (en) * 2002-08-08 2004-02-12 Epigenomics, Inc. Methods and nucleic acids for the analysis of CpG dinucleotide methylation status associated with the calcitonin gene
US20040029121A1 (en) * 2002-08-08 2004-02-12 Susan Cottrell Methods and nucleic acids for the analysis of CpG dinucleotide methylation status associated with the calcitonin gene
EP1556402B1 (en) * 2002-09-25 2011-06-22 University of Massachusetts In vivo gene silencing by chemically modified and stable sirna
US7655785B1 (en) * 2002-11-14 2010-02-02 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
US7851150B2 (en) * 2002-12-18 2010-12-14 Third Wave Technologies, Inc. Detection of small nucleic acids
WO2004086949A2 (en) * 2003-03-25 2004-10-14 John Wayne Cancer Institute Dna markers for management of cancer
US20050059024A1 (en) * 2003-07-25 2005-03-17 Ambion, Inc. Methods and compositions for isolating small RNA molecules
US7683036B2 (en) * 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
US8106180B2 (en) * 2003-08-07 2012-01-31 Whitehead Institute For Biomedical Research Methods and products for expression of micro RNAs
US20050037362A1 (en) * 2003-08-11 2005-02-17 Eppendorf Array Technologies, S.A. Detection and quantification of siRNA on microarrays
EA009376B1 (en) * 2003-11-10 2007-12-28 Нокссон Фарма Аг Nucleic acids specifically binding bioactive ghrelin
EP1732650A4 (en) * 2004-03-27 2008-06-11 Univ Arizona Composition and method for cancer treatment
US7365058B2 (en) * 2004-04-13 2008-04-29 The Rockefeller University MicroRNA and methods for inhibiting same
CA2566519C (en) * 2004-05-14 2020-04-21 Rosetta Genomics Ltd. Micrornas and uses thereof
US7642348B2 (en) * 2004-10-04 2010-01-05 Rosetta Genomics Ltd Prostate cancer-related nucleic acids
US20060078894A1 (en) * 2004-10-12 2006-04-13 Winkler Matthew M Methods and compositions for analyzing nucleic acids
FR2877350B1 (en) * 2004-11-03 2010-08-27 Centre Nat Rech Scient IDENTIFICATION AND USE OF miRNAs INVOLVED IN THE DIFFERENTIATION OF CELLS FROM MYELOID LEUKEMIA
ES2534304T3 (en) * 2004-11-12 2015-04-21 Asuragen, Inc. Procedures and compositions involving miRNA and miRNA inhibitor molecules
US20070009484A1 (en) * 2005-02-08 2007-01-11 Board Of Regents, The University Of Texas System Compositions and methods involving MDA-7 for the treatment of cancer
US7495073B2 (en) * 2005-03-24 2009-02-24 Asia Hepato Gene Company Short isoform of Annexin A10 at chromosome 4q, termed Annexin 10s (ANXA10s) and methods of use
JP2008539731A (en) * 2005-05-02 2008-11-20 コールド スプリング ハーバー ラボラトリー Compositions and methods for diagnosis and treatment of cancer
GB0601102D0 (en) * 2006-01-19 2006-03-01 Nuclea Biomarkers Llc Kinase Peptides And Antibodies
US20070065844A1 (en) * 2005-06-08 2007-03-22 Massachusetts Institute Of Technology Solution-based methods for RNA expression profiling
JP2008543288A (en) * 2005-06-09 2008-12-04 エポック バイオサイエンシズ インコーポレーティッド Improved primer-based amplification method
IL177006A0 (en) * 2005-08-02 2006-12-10 Veridex Llc Predicting bone relapse of breast cancer
US20070041934A1 (en) * 2005-08-12 2007-02-22 Regents Of The University Of Michigan Dendrimer based compositions and methods of using the same
WO2007144985A1 (en) * 2006-06-16 2007-12-21 Taisho Pharmaceutical Co., Ltd. Use of rpn2 gene expression inhibitor
US20080076674A1 (en) * 2006-07-06 2008-03-27 Thomas Litman Novel oligonucleotide compositions and probe sequences useful for detection and analysis of non coding RNAs associated with cancer
WO2008073915A2 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. Micrornas differentially expressed in leukemia and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070161004A1 (en) * 2004-05-28 2007-07-12 David Brown Methods and compositions involving microRNA
US20070054287A1 (en) * 2005-05-31 2007-03-08 Applera Corporation Method for identifying medically important cell populations using micro rna as tissue specific biomarkers
WO2007073737A1 (en) * 2005-12-29 2007-07-05 Exiqon A/S Detection of tissue origin of cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"POSTER ABSTRACTS", ANNALS OF SURGICAL ONCOLOGY, SPRINGER-VERLAG, NE, vol. 15, no. 1, 29 January 2008 (2008-01-29), pages 33 - 64, XP019568707, ISSN: 1534-4681 *
LIANG YU ET AL: "Characterization of microRNA expression profiles in normal human tissues", BMC GENOMICS, BIOMED CENTRAL, LONDON, GB, vol. 8, no. 1, 12 June 2007 (2007-06-12), pages 166, XP021027980, ISSN: 1471-2164 *
LU JUN ET AL: "MicroRNA expression profiles classify human cancers", NATURE, NATURE PUBLISHING GROUP, GB, vol. 435, no. 7043, 9 June 2005 (2005-06-09), pages 834 - 838, XP002485555 *

Also Published As

Publication number Publication date
EP2260110A2 (en) 2010-12-15
WO2009100430A2 (en) 2009-08-13
US20140141423A1 (en) 2014-05-22
US20090263803A1 (en) 2009-10-22
EP2260110B1 (en) 2014-11-12

Similar Documents

Publication Publication Date Title
WO2009100430A3 (en) miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS
Zhu et al. ncRAN, a newly identified long noncoding RNA, enhances human bladder tumor growth, invasion, and survival
Siefker-Radtke Urachal adenocarcinoma: a clinician's guide for treatment
Kang et al. A mathematical model for microRNA in lung cancer
CN103667516B (en) Kit or biological chip for detecting miRNAs for early colonic adenocarcinoma and rectal adenocarcinoma
EP3683320A3 (en) Mirna fingerprint in the diagnosis of lung cancer
WO2005111211A3 (en) Micronas and uses thereof
Su et al. microRNA-184 functions as tumor suppressor in renal cell carcinoma
Esparza-Baquer et al. MicroRNAs in cholangiopathies: Potential diagnostic and therapeutic tools
CN102399889A (en) Method for detecting long-chain non-coding ribonucleic acid (RNA)-HOTAIRM1
NZ598652A (en) Cancer cell apoptosis
Barbieri et al. Tissue-based molecular markers for bladder cancer
Yi et al. Association of MiR-155 Expression with Prognosis in Resected Stage III Non-small Cell Lung Cancer.
Thapa et al. Clinico-pathological study of colorectal carcinoma.
WANG et al. The role of microRNA in chronic myeloid leukemia
Chbani et al. Epithelioid sarcoma
Zedan The Dysregulation of mir-21 and mir-143 as a clinical Marker for Cancer Stem Cells in Tissue Samples of Iraqi Male Patients with Gastrointestinal Sarcoma
Qureshi et al. BLADDER CARCINOMA;: MICRO-RNAS: EXPRESSION OF MIR-145 IN PATIENTS, AS A NEW DIAGNOSTIC APPROACH
WO2003025135A3 (en) Genes associated with malignant neoplasms
Tourvas et al. Towards an extension of the two-variable model of carcinogenesis through oncogenes and tumour suppressor genes
Shields et al. Infant with an unusual pharyngeal mass
Zhan et al. Combined detection of tumor suppressor gene methylation and early diagnosis of lung cancer
Chun-tao et al. c-Met expression in esophageal squamous cell carcinoma tissues and its correlation with clinicopathological characteristics
Mangolini et al. MIR-501 DEPLETION INDUCES CELL CYCLE INHIBITION BY MTOR AND P53 MODULATION IN RENAL CARCINOMA
Galassi Aspetti diagnostici, strategie terapeutiche ed esito clinico dei tumori primitivi colangiocellulari insorti su cirrosi

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09709348

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009709348

Country of ref document: EP